GlaxoSmithKline Receives New Approval For Rotarix And Significant New Indication For Lamictal® (lamotrigine) In Japan
Main Category: GastroIntestinal / Gastroenterology
Also Included In: Regulatory Affairs / Drug Approvals; Pharma Industry / Biotech Industry
Article Date: 02 Jul 2011 - 1:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); 
email to a friend 
printer friendly 
opinions 
GlaxoSmithKline (GSK) announced that its rotavirus vaccine has received approval in Japan from the Ministry of Health, Labour and Welfare (MHLW) for use in infants to prevent gastroenteritis caused by rotavirus. RotarixTM is the first vaccine against rotavirus to be approved in Japan, and the third GSK vaccine to gain approval in Japan following the licences received for Cervarix® in 2009 and ArepanrixTM in 2010. It is expected to be available in Japan towards the end of the year, following the completion of national testing.
GSK also today gained approval for a significant new indication in Japan for Lamictal® (lamotrigine) Tablets 25mg and 100mg for the prevention of depressive episodes in adult patients with bipolar disorder. Lamotrigine is the first treatment in Japan to be classified for bipolar disorder. It is currently licensed in Japan as an adjunctive therapy for epileptic seizures in patients inadequately controlled by other antiepileptic drugs. It will be available for the new indication immediately.
Philippe Fauchet, President of GlaxoSmithKline Japan, commented: "These two approvals demonstrate the clear progress GSK is making in bringing more products that offer real value to patients in Japan. In total, we have now received 24 new product approvals, including eight new chemical entities, since 2009. We are particularly pleased to contribute to preventative healthcare with the approval of our rotavirus vaccineand we hope this will help to reduce the significant burden of this disease in Japan. In addition, with the new indication for lamotrigine, we now have the first approved treatment for bipolar disorder available in Japan to help prevent depressive episodes in adults with bipolar disorder."
RotarixTM is an oral vaccine for the prevention of gastroenteritis caused by rotavirus. It is given as a two-dose schedule to babies from the age of 6 weeks and can be completed by 10 weeks of age. It is currently approved in over 120 countries worldwide.
In Japan, approximately 1 in every 15 children will require hospitalization due to rotavirus-related diarrhoea by their fifth year of life.iiGrowing evidence suggests that the introduction of rotavirus vaccines substantially reduce severe diarrhoea in young children. In Brazil hospitalisations due to rotavirus gastroenteritis decreased by almost 60% just one year after the introduction of universal mass vaccination.i
In April 2009, the World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) recommended that rotavirus vaccination be included in all national immunisation programmes. Based on this decision, the WHO awarded global prequalification to RotarixTM. Since its first launch in 2007 100 million doses have been delivered which means that around 50 million children across the world have been vaccinated against rotavirus.Lamictal® (lamotrigine) was approved in Japan in October 2008 as adjunctive therapy for seizures in patients inadequately controlled (partial seizures, generalized seizures, tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome) by other antiepileptic drugs.
Lamotrigineis recommended by international guidelines as maintenance therapy for patients with bipolar disorder.iii-ix Lamotrigine is currently approved in more than 110 countries for indications related to epilepsy and in more than 80 countries for indications related to bipolar disorder.
It is now also approved for the prevention of depressive episodes in adults aged 18 years and over with bipolar disorder.
References
i Safadi M et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Brazil. Poster presentation at ESPID.
ii J Infect Dis. 2005 Sep 1;192 Suppl 1:S106-10.
iii Am J Psychiatry 159:4, April 2002 Supplement
iv National Institute for Health and Clinical Excellence (NICE). 2006.
v Yatham LN, et al. Bipolar Disord 2006;8:721 - 739.
vi Grunze H, et al. World J Biol Psychiatry 2002;3:115 - 124.
vii Scottish Intercollegiate Guidelines Network (SIGN). 2005.
viii Calabrese JR, et al. J Clin Psychiatry 2004;65:569 - 579.
ix Suppes T, et al. J Clin Psychiatry 2005;66:870 - 886.
Source: GlaxoSmithKline
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.
View the original article here
Read More ..